We have helped to secure more than $80 billion in jury verdicts and settlements since 1955.
The Ozempic NAION lawsuit alleges that Novo Nordisk failed to warn patients and doctors that semaglutide can cause non-arteritic anterior ischemic optic neuropathy (NAION), a form of optic nerve damage producing sudden, typically permanent vision loss in one or both eyes. Federal vision-loss cases are consolidated in MDL No. 3163, before Hon. Karen Spencer Marston in the U.S. District Court for the Eastern District of Pennsylvania. As of May 1, 2026, 86 NAION cases were pending in the MDL.
As of May 1, 2026, 86 cases are pending in MDL No. 3163, the federal NAION vision-loss litigation, with additional state-court claims filed in New Jersey, Indiana, and other jurisdictions. On February 23, 2026, Hon. Karen Spencer Marston entered a case management order appointing the Plaintiffs’ Executive Committee, including Levin Papantonio Rafferty attorney Cameron Stephenson [VERIFY: confirm Stephenson on 3163 PEC specifically]. Bellwether trials are reportedly scheduled for late 2026 and early 2027 [VERIFY: confirm current schedule].
If you or a loved one took a GLP-1 RA like Ozempic and suffered from sudden vision loss (NAION), call us today for a free, no-obligation case evaluation. Call (800) 277-1193 or complete a short Free Evaluation Form.
I agree to LP's Policies and Disclaimers, and I consent to receive emails, calls, and texts, including those made by an automated system, from or on behalf of Levin Papantonio. My consent is effective even if my number is listed on any state, federal or corporate do-not-call registry. I understand my consent to receive automated marketing calls/texts is not required as a condition of purchasing any services and that I can revoke my consent, at any time, by writing to contact@levinlaw.com..
By selecting "I Agree" below and clicking the "Submit for Free Evaluation” button, I agree to the POLICIES AND DISCLAIMERS, including arbitration provision therein, and consent to receive marketing emails, calls and/or texts, including those made using an automated system and/or artificial/prerecorded voice message, from or on behalf of Levin Papantonio Law Firm (“LP”) / Pensacola, FL / 850-435-7000 / levinlaw.com, regarding their services in response to my inquiry at the telephone number(s) provided above, even if that number is currently listed on any state, federal or corporate Do Not Call registry. I understand my consent to receive automated marketing calls/texts is not required as a condition of purchasing any services. I can revoke my consent at any time. Review LP's Terms and Conditions and Privacy Policy here.
Opt in to Receive Calls, Text Messages, and Emails
By checking the below box and clicking “SUBMIT”, I agree to the Terms of the Policies and Procedures of the referenced entity, including individual arbitration provisions therein. I also consent to receive marketing emails, calls, and/or text messages, including those made using an automated system and/or artificial/prerecorded voice message (including artificial intelligence (AI)-generated voices), from or on behalf of the referenced entity regarding its services and/or my inquiry at the telephone number provided above, even if currently listed on any state or federal Do Not Call registry. I understand that my consent to receive automated marketing calls/texts is not required as a condition of purchasing any services, and that I may opt out of such calls/texts at any time.
Our law firm is dedicated to offering victims the latest updates on Ozempic lawsuits. We frequently update this page to ensure you have the most current news and information relevant to your claim.
On February 23, 2026, the Hon. Karen Spencer Marston entered a case management order appointing attorneys to the Plaintiffs’ Executive Committee in the consolidated federal litigation involving glucagon-like peptide-1 (GLP-1) receptor agonist drugs and alleged non-arteritic anterior ischemic optic neuropathy (NAION).
This order establishes the leadership structure for plaintiffs in the GLP-1 Vision Loss litigation. Judge Marston appointed Cameron Stephenson and other experienced attorneys to serve on the Plaintiffs’ Executive Committee (PEC), which is responsible for coordinating litigation strategy, overseeing discovery, and advancing plaintiffs’ claims on a nationwide basis.
Reuters flagged the Ozempic/GLP-1 weight-loss litigation as a top mass tort to watch heading into 2026, with lawsuits mounting against Novo Nordisk and Eli Lilly over alleged side effects of their blockbuster drugs. About 3,000 cases have already been filed, and that number is expected to grow as use of GLP-1 medications expands. The lawsuit claims that the drugs can cause vision-threatening eye conditions.
A federal court has created a new multidistrict litigation, MDL No. 3163, for lawsuits alleging that Ozempic caused non-arteritic anterior ischemic optic neuropathy, or NAION, a serious condition that can result in sudden and permanent vision loss. The Judicial Panel on Multidistrict Litigation centralized these vision loss cases in the Eastern District of Pennsylvania. The court recognized NAION as a distinct injury that requires focused judicial review. This new MDL will allow claims involving GLP-1-related vision loss to move forward in a coordinated and efficient manner.
As of November 3, more than 2,900 GLP-1 lawsuits are pending in the multidistrict litigation, according to JPML reports.
The month of October started off with 2,809 lawsuits pending in the GLP-1RA MDL, according to JPML reports.
On September 11, Eli Lilly filed a motion seeking to centralize all federal lawsuits alleging vision loss (NAION) linked to GLP-1RAs. The company urged that these cases either be incorporated into MDL 3094 or assigned as a new MDL under Judge Marston’s oversight.
On September 6, 2025, Judge Gene E.K. Marston issued a ruling clarifying the types of claims allowed under MDL 3094. Plaintiffs may now proceed with cases involving:
The JPML reported that as of September 2, 2025, there are 2,676 actions pending in the Ozempic lawsuit MDL.
On August 1, 2025, the JPML reported there are 2,190 cases pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.
As of July 1, 2025, there are 1,997 lawsuits pending in the GLP-1RA multidistrict litigation.
On June 6, 2025, the European Medicines Agency’s (EMA) safety committee concluded that Novo Nordisk’s semaglutide-containing drugs—including diabetes treatment Ozempic—may cause rare but serious cases of non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and painless vision loss in one eye due to optic nerve damage.
The EMA’s review, launched in December 2024, found that the risk of developing NAION more than doubled in patients taking semaglutide compared to those on other diabetes medications, with an estimated frequency of up to 1 in 10,000. Based on its findings, the EMA has advised updating prescribing information to list NAION as a “very rare” side effect.
This regulatory action marks the first official link between semaglutide use and NAION, reinforcing concerns raised by earlier studies and intensifying scrutiny of these popular GLP-1 receptor agonists in ongoing semaglutide lawsuits. [SOURCE: Reuters]
As of June 2, 2025, the JPML reports there are 1,882 cases pending in the MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.
A Maryland man filed a lawsuit against Novo Nordisk, claiming he developed non-arteritic anterior ischemic optic neuropathy (NAION) after taking Ozempic for diabetes.
Toward the end of last month, the Honorable Karen Spencer Marson entered an order specifying the dates for status conferences in the GLIP-1RA MDL. A status conference is scheduled to take place March 18.
A study published January 30, 2025, found that medications like Ozempic, commonly used to treat diabetes and aid in weight loss, may be linked to rare eye conditions that can cause vision loss or even blindness.
A review published in JAMA Ophthalmology detailed nine cases where patients experienced significant vision problems after taking these drugs. The conditions seen include non-arteritic anterior ischemic optic neuropathy (NAION). This condition causes sudden vision loss from reduced blood flow to the optic nerve.
The number of lawsuits against GLP-1 drugmakers has now reached 1,443. More than 100 new cases were added in early February.
The next status conference is set for February 24. During this meeting, attorneys will talk about the case’s progress and the next steps.
As of November 1, the total number of pending cases in the Ozempic MDL is 1,221.
The month started with 101 new cases that were added to the multidistrict litigation during September. According to the JPML, 1,090 cases are now pending in the GLIP-1RA MDL.
Early discovery and motion practice have been scheduled on two issues: preemption (whether federal law overrides the case) and whether warning labels were clear enough. The plaintiffs are asking to include marketing discovery early, arguing that it’s crucial because drug companies often downplay risks in their marketing, which could impact the case.
The month of August ended with a total of 869 pending lawsuits in the GLP-1RA Products Liability Litigation MDL.
On July 14, 2024, the Hon. Karen Spencer Marston entered several case management orders (CMOs) in the GLP-1RAs Product Liability MDL.
As of May 1, 2024, the Judicial Panel on Multidistrict Litigation (JPML) reports 87 cases are pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.
On May 8, 2024, U.S. District Judge Gene E.K. Pratter issued Case Management Order No. 6, which expanded the Leadership Structure for the Ozempic lawsuits [IN RE: GLUGAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION (MDL 3094)]. Levin Papantonio Rafferty (LPR) Attorney Cameron Stephenson was appointed to the Plaintiffs’ Executive Committee in this MDL.
The first status conference for the Ozempic multidistrict litigation occurred last week, gathering attorneys from Novo Nordisk and plaintiffs who have either filed cases or are seeking positions in the plaintiffs’ attorney leadership group for the MDL. This initial case management meeting was conducted in a federal court in Pennsylvania.
If you have been hurt by Ozempic, you may be able to file a lawsuit. You could get compensation for your injury. Find out in a free phone consultation.
Schedule Your Free Evaluation
Compensation in an Ozempic NAION lawsuit may include past and future medical expenses, lost income and diminished earning capacity, pain and suffering, loss of enjoyment of life, costs of vision aids and home modifications, and potentially punitive damages. No global settlement has been reached, and bellwether trial outcomes will likely shape valuation. Settlement values in similar pharmaceutical product-liability cases have varied widely based on injury severity, duration, and documented losses.
Our attorneys will fight to get you the maximum financial compensation to cover the losses you have suffered from vision loss after taking Ozempic.
Ozempic belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RA). This drug contains the active ingredient semaglutide.
The Semaglutide Class
Semaglutide is a class of prescription drug used to control high blood sugar in individuals with type 2 diabetes mellitus. It is classified as a GLP-1 Receptor Agonist Analog-Type drug. The medication mimics a natural human glucagon-like peptide (GLP-1) to slow the passing of food through the stomach.
How the Weight-Loss Drugs Differ
Patients receive Ozempic as a subcutaneous injection. Ozempic is designed for the treatment of type 2 diabetes at doses of 0.5 to 1 mg weekly.
You may qualify to file an Ozempic NAION lawsuit if you were prescribed a semaglutide drug (Ozempic, Wegovy, or Rybelsus) or another GLP-1 receptor agonist and were later diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), causing permanent vision impairment. Eligibility generally requires a formal NAION diagnosis from a treating ophthalmologist, prescription records showing GLP-1 use before symptom onset, and medical documentation connecting the two. Off-label use for weight loss does not disqualify a claim.
Our law firm is currently investigating cases on behalf of individuals who:
A free consultation will tell you what you need to know about your eligibility to file an Ozempic lawsuit.
The Ozempic NAION lawsuit covers non-arteritic anterior ischemic optic neuropathy (NAION), an ischemic injury to the optic nerve caused by reduced blood flow that produces sudden, typically painless, usually permanent vision loss in one eye, sometimes progressing to involve the second eye. Related ophthalmic injuries under investigation include other forms of ischemic optic neuropathy and worsening of pre-existing diabetic retinopathy connected to semaglutide use. NAION is classified under ICD-10 code H47.01 [VERIFY: confirm specific subcode H47.011 / H47.012 / H47.013 / H47.019].
The primary legal issue could be whether the Ozempic manufacturer, Novo Nordisk, knew or should have known about the heightened risks for NAION vision impairment that these drugs posed to users and failed to warn doctors and patients of this risk.
If you or a loved one took a GLP-1 RA such as Ozempic and suffered from vision loss, contact us today for a free, no-obligation case evaluation. Call us at (800) 277-1193 or fill out our brief Free Evaluation Form.
The deadline to file an Ozempic NAION lawsuit is governed by the statute of limitations in the state where the injury occurred, generally ranging from one to six years from the date the injury was diagnosed or reasonably discovered. Kentucky, Louisiana, and Tennessee have the shortest periods at one year. Florida, where Levin Papantonio is based, currently allows two years for personal injury claims following the 2023 statutory change. Because deadlines vary and the discovery rule applies, prompt consultation with an attorney is essential.
Have you or a loved one taken a GLP-1 RA like Ozempic and been diagnosed with vision loss, or NAION? Reach out to us today for a complimentary case evaluation with no obligation. Call (800) 277-1193or complete our shortFree Evaluation Form.
Yes, Ozempic and other semaglutide medications have been linked to non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of optic nerve damage that can cause sudden, typically permanent vision loss in the affected eye. A 2024 JAMA Ophthalmology study reported that patients with type 2 diabetes prescribed semaglutide were more than four times as likely to develop NAION than comparable non-users, and the European Medicines Agency formally listed NAION as a “very rare” side effect of semaglutide in June 2025.
NAION (non-arteritic anterior ischemic optic neuropathy) is a sudden loss of blood flow to the optic nerve that causes sudden, painless vision loss in one eye, often noticed upon waking. The vision loss is typically permanent because the optic nerve cannot regenerate, and roughly 15% of NAION patients eventually develop the condition in the second eye. Doctors sometimes describe NAION as a “stroke of the optic nerve.”
No, blurry vision from Ozempic is usually not NAION. Mild, temporary blurry vision in the first weeks of treatment is a known Ozempic side effect, typically caused by rapid blood-sugar changes affecting the eye’s lens, and it usually resolves as the body adjusts. NAION is sudden, painless vision loss in one eye that is typically permanent and constitutes a medical emergency. Lawsuit eligibility is based on a confirmed NAION diagnosis, not on temporary blurry vision.
Sudden vision loss in one eye while taking Ozempic requires immediate evaluation by an ophthalmologist or emergency department, because NAION is time-sensitive, and other causes of sudden vision loss can also require urgent treatment. After medical evaluation, ask your provider to document the diagnosis, the timing of symptoms, and your prescription history. If NAION is confirmed, consult a product-liability attorney about a potential claim before your state’s statute of limitations expires.
The deadline to file an Ozempic vision loss lawsuit depends on the statute of limitations in your state, which can be as short as one year (Kentucky, Louisiana, Tennessee) or as long as six years. Most states begin the clock when the injury was diagnosed or reasonably should have been discovered. Because deadlines vary and a missed deadline ends your right to sue, anyone with a NAION diagnosis following GLP-1 use should consult an attorney promptly.
Yes, you can file an Ozempic NAION lawsuit even if you took Ozempic off-label for weight loss rather than for type 2 diabetes. The legal claim is failure to warn about the NAION risk, which applies regardless of why the drug was prescribed. What matters for eligibility is documented prescription use of a covered semaglutide or GLP-1 drug, a confirmed NAION diagnosis, and a plausible time connection between drug use and onset of symptoms.
The GLP-1 NAION lawsuit covers patients who developed non-arteritic anterior ischemic optic neuropathy after using semaglutide-containing drugs (Ozempic, Wegovy, Rybelsus, manufactured by Novo Nordisk) and other GLP-1 receptor agonists, including Mounjaro, Zepbound, Trulicity, and Saxenda. Compounded versions and generic equivalents may be evaluated separately. Eligibility requires documented prescription use of a covered drug before the onset of NAION symptoms.
Settlement values for an Ozempic NAION lawsuit have not been formally established because the federal MDL has not reached a settlement, and no bellwether verdicts exist yet. Published analyst projections for permanent NAION vision loss claims have ranged from several hundred thousand to over one million dollars per case, with higher estimates for bilateral blindness, but these are projections only and not based on actual outcomes. An attorney can evaluate your specific medical records and damages to estimate potential value.
Vision loss from NAION linked to Ozempic is typically permanent because the optic nerve has limited capacity to regenerate after ischemic damage. There is currently no cure or treatment that reliably restores vision lost to NAION, and approximately 15% of NAION patients eventually develop the condition in the second eye. Patients with partial recovery may still qualify for a claim based on documented medical costs, pain, and suffering.
Most firms accepting Ozempic NAION claims set an upper age cutoff around 75 at the time of diagnosis, because NAION risk rises naturally with age, and older onset is harder to causally connect to drug use. There is no formal MDL age limit, and individual eligibility depends on medical evidence, prescription timing, and the specific facts of the diagnosis. Older patients with clear documentation may still be evaluated for a claim.
MDL No. 3163 covers federal lawsuits alleging vision loss (NAION) from GLP-1 drugs, while MDL No. 3094 covers federal lawsuits alleging gastrointestinal injuries such as gastroparesis from the same drug class. Both MDLs are consolidated in the U.S. District Court for the Eastern District of Pennsylvania before Hon. Karen Spencer Marston. The Judicial Panel on Multidistrict Litigation separated the vision claims into MDL 3163 in December 2025.
Supporting an Ozempic NAION claim typically requires a formal NAION diagnosis from a treating ophthalmologist (often based on dilated eye exam, optical coherence tomography, and visual field testing), prescription records confirming Ozempic or another GLP-1 drug use before symptom onset, and medical records ruling out other common NAION causes such as giant cell arteritis. An attorney works with medical record consultants to assemble this evidence for the MDL Plaintiff Fact Sheet.
Ozempic vision loss lawsuits began emerging in 2024 after a JAMA Ophthalmology study reported elevated NAION rates in semaglutide users. The first cases were filed within MDL 3094, the general GLP-1 MDL, and in December 2025, the Judicial Panel on Multidistrict Litigation created MDL 3163 specifically for NAION vision-loss claims. The European Medicines Agency formally linked semaglutide to NAION in June 2025.
No, no global settlement has been reached in the Ozempic NAION lawsuit (MDL 3163) as of May 2026. The MDL is in early proceedings with case management orders being entered, the Plaintiffs’ Executive Committee recently appointed, and bellwether trials reportedly scheduled for late 2026 and early 2027. Global resolutions in mass torts typically follow bellwether trial outcomes, so timing remains uncertain.
As of May 1, 2026, 86 cases are pending in MDL No. 3163, the federal multidistrict litigation for GLP-1-related NAION vision loss in the Eastern District of Pennsylvania. Additional vision-loss cases, reported at over 120 total as of March 2026, are pending in state courts, with active filings in New Jersey and Indiana. The federal case count is expected to grow as more patients receive NAION diagnoses.
The main warning sign of NAION is sudden, painless vision loss in one eye, often noticed upon waking, ranging from a dim or shadowed area in part of the visual field to substantial loss of central or peripheral vision. Other potential symptoms include loss of color contrast, an enlarged blind spot, and a swollen optic disc visible on eye exam. Sudden vision loss requires immediate evaluation by an ophthalmologist or the emergency department.
Novo Nordisk is being sued because plaintiffs allege the company knew or should have known that semaglutide carried a risk of NAION vision loss and failed to warn patients and prescribing physicians on the drug label. The European Medicines Agency formally listed NAION as a “very rare” side effect of semaglutide in June 2025, while the U.S. prescribing information has not historically listed NAION prominently [VERIFY: confirm current U.S. Ozempic label status before publishing].
Levin Law
Levin Law